Answers are grounded in this paper and cite their sources.
SUMMARY Alternatives to platelet transfusions are important in preventing the adverse events associated with platelet transfusions. The use of platelet alternatives has not been extensively compared with platelet transfusions, although studies suggest that bleeding can be controlled and transfusions prevented. A variety of pharmacologic agents are available, which generally work by augmenting different hemostatic mechanisms. In addition to pharmacologic agents, recombinant activated factor VII is available for controlling inherited qualitative platelet disorders such as Glanzmann’s thrombasthenia. For the treatment of chemotherapy‐induced thrombocytopenia, the use of growth factors may shorten the duration of thrombocytopenia and prove to be an approach for reducing or preventing platelet transfusions. Although interesting research has been carried out for several decades in the aim of developing a platelet substitute, it is unlikely that a platelet substitute will be available for clinical use in the near future.
No takes yet. Share an insight, caveat, or question.
Thomas S. Kickler (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: